Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study

GOTHENBORG, Sweden, July 14 PharmaSurgics AB.successfully completes Phase I clinical study showing their novel candidatedrug PXL01 is safe and well tolerated. Initially developed to preventpost-surgical adhesion formation following hand surgery the product combinesthe pharmacological effect of PXL01 with the physical barrier effect of thevehicle, and has the potential to be the first anti-adhesion drug on themarket. 'These results provide the foundation for proceeding to the nextphase, proof of concept study in patients,' said Fredrik Sjovall, CEO ofPharmaSurgics, adding 'the proof of concept study in patients of flexortendon repair surgery is scheduled to start in December 2009.'

Post-surgical adhesions are bands of scar tissue connecting anatomicsites in the body that should not normally be connected. These develop afteralmost every type of surgery and cause symptoms such as restricted jointmobility, chronic pain, intestinal obstruction and re-operativecomplications. Following flexor tendon repair surgery post-surgical adhesionslead to decreased strength and function of the affected joints, extensivepost-operative physiotherapy and extended periods of sick leave.

About PharmaSurgics

PharmaSurgics in Sweden AB is a Gothenburg based biotech company thatdevelops and commercializes a novel treatment for preventing harmful scarringand promoting wound healing after surgery. PharmaSurgics product concept isbased on proprietary synthetic peptides which have strong anti-inflammatoryand anti-infectious properties. The company was founded in 2005, based onextensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarkerat Sahlgrenska University Hospital, Gothenborg, Sweden. PharmaSurgics is aKarolinska Development portfolio company.For further information please contact Fredrik Sjovall, CEO of PharmaSurgics Ph: +46-31-762-29-01 Email: [email protected]

SOURCE PharmaSurgics AB

Latest Press Release on General News

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...

Dr. Andres Bustillo Responds to Miami's Growing Interest in Facelift Procedures

In response to the growing demand for facelifts in Miami , Dr. Andres Bustillo , a renowned board-certified facial plastic surgeon, is offering advanced and time-proven techniques in f...